The global alopecia treatment (hair loss) market is witnessing significant growth due to the rising prevalence of hair loss conditions, increasing awareness about available treatment options, and advancements in technology. Alopecia can affect individuals of all ages and genders, leading to emotional distress and a negative impact on self-esteem. The market offers various treatment approaches, including medications, surgical procedures, and hair transplant techniques. With a focus on improving hair growth and restoring confidence, the alopecia treatment market continues to evolve, providing solutions to individuals experiencing hair loss.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-alopecia-treatment-hair-loss-market
Data Bridge Market Research analyses that the Alopecia Treatment (Hair Loss) Market is valued and will reach USD 6,266.73 million by 2030, growing at a CAGR of 7.12% during the forecast period of 2023 to 2030. The rising prevalence of hair loss conditions, such as androgenetic alopecia, alopecia areata, and traction alopecia, is a major driver for the global alopecia treatment market. The growing number of individuals affected by hair loss fuels the demand for effective treatment options.
Key Findings of the Study
Rise in the geriatric population is expected to drive the market's growth rate
The rise in the geriatric population globally has led to an increased demand for alopecia treatment. As individuals age, they often experience age-related hair loss, which can impact their appearance and self-esteem. Many older individuals are motivated to seek effective treatment options to address this concern and maintain a more youthful appearance. This growing desire to combat age-related hair loss has driven the demand for alopecia treatment among the elderly population.
Report Scope and Market Segmentation
Report Metric
|
Details
|
Forecast Period
|
2023 to 2030
|
Base Year
|
2022
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
Segments Covered
|
Disease Type (Alopecia Areata, Cicatricial, Traction, Androgenetic Alopecia, Non‒Cicatricial Alopecia, Traction Alopecia, Ciatricial Alopecia, Alopecia Totalis, Alopecia Universalis, Others), Treatment (Localized Therapies, Medical Devices, Systemic Therapies, Herbal Treatment, Hair Transplant Services, Low Level Laser Therapy), Drug Type (Topical Agents, Oral Drugs, Injections, Corticosteroids, Immunosuppressants, Minoxidil, Finasteride, Others), Gender (Male, Female), Age Group (Below 18 Years, 18-34 Years, 35-49 Years, Above 50 Years), Form (Topical, Oral, Parenteral), Distribution Channel (Hospital Pharmacy, Drug Stores, Dermatology Clinics, Retail Pharmacy, Online Pharmacy, Others), End-Users (Hospitals, Dermatologic, and Trichology Clinics, Aesthetic Clinics, Specialty Clinics, Homecare, Others)
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
Market Players Covered
|
Johnson & Johnson Private Limited (U.S.), GSK plc (U.K.), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Cipla Inc. (U.S.), Endo International plc (Ireland), Zydus Group (India), Abbott (U.S.), Aurobindo Pharma (India), Dr. Reddy’s Laboratories Ltd. (India), Perrigo Company plc (Ireland), Curallux, LLC. (U.S.), DR. KURT WOLFF GMBH & CO. KG (Germany), WOCKHARDT (India), Sun Pharmaceutical Industries Ltd.(India), Concert Pharmaceuticals. (U.S.), Cipla Inc. (India), DAIICHI SANKYO COMPANY, LIMITED. (Japan) among others
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The alopecia treatment (hair loss) market is segmented on the basis of disease type, treatment, gender, form, end-users, and distribution channel.
- On the basis of disease type, the global alopecia treatment (hair loss) market is segmented into non‒cicatricial alopecia, traction alopecia, ciatricial alopecia, and others. non‒cicatricle alopecia segment is expected to dominate the market with 54.80% market share in the forecast period of 2023-2030 due to its the most common type of alopecia which affects the major population
2023 年，非瘢痕性脫髮預計將成為市場疾病類型細分市場的主導
2023 年，非瘢痕性脫髮預計將佔據市場主導地位，因為它是影響大多數民眾的最常見的脫髮類型。雄性禿是男性和女性日常脫髮的原因之一。這種脫髮形式預計會影響 5,000 萬男性和 3,000 萬名女性，在 2023-2030 年的預測期內，市佔率為 54.80%
- 根據治療，全球脫髮治療（脫髮）市場分為局部治療、醫療設備、全身性治療和草藥治療。局部治療領域預計將在 2023-2030 年預測期內以 6.6% 的複合年增長率主導脫髮治療（脫髮）市場，因為局部治療是一線治療療法，並且如果皮質類固醇注射後出現新頭髮生長，通常會在四周內可見。這些類型的療法被認為易於使用且副作用最小。
- 根據性別，全球脫髮治療（脫髮）市場分為男性和女性。預計在 2023-2030 年的預測期內，男性將以 6.6% 的複合年增長率主導脫髮治療市場，因為根據美國國家醫學圖書館和美國脫髮協會的數據，近 50% 的男性在 50 歲之前會經歷某種程度的脫髮。雄性激素是導致男性雄性禿的主要原因。
- 根據形式，全球脫髮治療（脫髮）市場分為外用、口服和腸外治療。由於全身不良事件和藥物交互作用的風險較低，預計外用藥物將在 2023-2030 年的預測期內佔據脫髮治療（脫髮）市場的主導地位，市場份額為 49.46%。
預計到 2023 年，局部用藥將佔據脫髮治療市場的主要部分
2023 年，由於全身不良事件和藥物交互作用的風險較低，預計外用藥物將主導脫髮治療市場，接受外用製劑治療的患者中約有 40% 至 50% 將在治療約六個月後重新長出頭皮毛髮，在 2023-2030 年的預測期內佔據 49.46% 的市場份額。
- 根據最終用戶，全球脫髮治療（脫髮）市場分為皮膚病中心、醫院和家庭醫療保健。由於皮膚病中心擁有專業人員，脫髮和修復手術的盛行率不斷上升，加上處方藥的廣泛應用，皮膚病中心部門預計將在 2023-2030 年的預測期內以 6.2% 的份額佔據脫髮治療（脫髮）市場的主導地位。
- 根據分銷管道，全球脫髮治療（脫髮）市場分為藥局、零售和直接招標。由於脫髮治療中，一些藥物是非處方藥，一些是處方藥，預計藥房部門將在 2023-2030 年預測期內以 6.3% 的複合年增長率主導脫髮治療（脫髮）市場。藥局是患者依自身需求購買藥品的首選場所。
主要參與者
Data Bridge Market Research 認為以下公司是掉髮治療市場的主要 參與者，它們是強生私人有限公司（美國）、葛蘭素史克公司（英國）、默克公司（美國）、輝瑞公司（美國）、太陽製藥工業有限公司（印度）、梯瓦製藥工業有限公司（以色列）、西普拉（美國）、Endo International plclc（愛爾蘭）、Zydus Group（愛爾蘭）、Abindo（美國）、雅培印度）
市場開發
- 2021年，輝瑞發表了富有成效的2b/3期脫髮ritlecitinib試驗的結果。一類新的共價激酶抑制劑，包括利他替尼，以 Janus 激酶 3 (JAK3) 和肝細胞癌 (TEC) 激酶家族中表達的酪胺酸激酶成員為初始標靶。
- 2020 年，禮來公司獲得 FDA 頒發的用於治療斑禿的巴瑞替尼突破性認定。這一頭銜不僅讓該公司加快了產品開發進程，還使其獲得了獎勵。
- 2019年，WON TECH 株式會社的 HairBoom Air 獲得了 FDA 批准。該設備利用低強度雷射治療脫髮，經證實佩戴舒適、使用方便。據報道，該設備每天只需使用 18 分鐘即可產生有效的效果。此項核准有助於增強該公司的產品組合。
區域分析
從地理上看，脫髮治療市場報告涵蓋的國家有北美洲的美國、加拿大和墨西哥，歐洲的德國、法國、英國、荷蘭、瑞士、比利時、俄羅斯、義大利、西班牙、土耳其，歐洲的其他地區，中國、日本、印度、韓國、新加坡、馬來西亞、澳洲、泰國、印尼、菲律賓，亞太地區（APAC）的其他亞太地區（APAC），沙烏地阿拉伯、美國地區的其他地區（APAC）、美國地區（APAC），美國地區的其他地區（APAC）
根據 Data Bridge 市場研究分析：
2023-2030 年預測期內，北美是脫髮治療市場的主導地區
北美佔據市場主導地位，並將在預測期內繼續保持其主導地位。脫髮的常見形式以及脫髮患者所經歷的影響推動了區域市場的發展。然而，區域市場成長的主要動力是市場不斷擴張並吸引新的競爭對手。
預計2023-2030 年預測期內亞太地區將成為脫髮治療市場成長最快的地區
由於脫髮護理治療的使用增加以及脫髮患病率的上升，亞太地區在預測期內將經歷最高的增長率。此外，改善發展中國家的醫療監管環境有望吸引國際參與者投資並利用現有的市場機會
有關脫髮治療（脫髮）市場 報告的更多詳細信息，請點擊此處 - https://www.databridgemarketresearch.com/reports/global-alopecia-treatment-hair-loss-market
